Details

Last Funding Type

Series C

Last Funding Money Raised

$40M

Industries

Biotechnology,Health Diagnostics,Therapeutics

Founded date

Jun 8, 2011

Number Of Employee

1 - 10

Operating Status

Active

ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy.

ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.